Business Wire

Goldfinch Bio Announces Positive Preliminary Data from Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Focal Segmental Glomerular Sclerosis ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced ...
Business Wire

Goldfinch Bio Announces Initiation of Open-Label Extension Study for Patients with Focal Segmental Glomerular Sclerosis (FSGS) Enrolled in Phase 2 Clinical Trial of GFB-887

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced ...
Nature

Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice

Figure 2: GFB-111 binds PDGF and inhibits 125 I-PDGF binding to its receptor on NIH 3T3 cells. In this study we have used a new approach to inhibiting receptor tyrosine kinase signaling by targeting ...